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 2012 EMBO Molecular MedicineEndometriosis is found in 5–15% of women of reproductive age and is more
frequent in relatives of women with the disease. Activation of KRAS results in
de novo endometriosis in mice, however, activating KRAS mutations have not
been identified in women. We screened 150 women with endometriosis for a
polymorphism in a let-7 microRNA (miRNA) binding site in the 3’-UTR of KRAS and
detected a KRAS variant allele in 31% of women with endometriosis as opposed to
5% of a large diverse control population. KRAS mRNA and protein expression were
increased in cultured endometrial stromal cells of women with the KRAS variant.
Increased KRAS protein was due to altered miRNA binding as demonstrated in
reporter assays. Endometrial stromal cells from women with the KRAS variant
showed increased proliferation and invasion. In a murine model, endometrial
xenografts containing the KRAS variant demonstrated increased proliferation and
decreased progesterone receptor levels. These findings suggest that an inherited
polymorphism of a let-7 miRNA binding site in KRAS leads to abnormal endo-
metrial growth and endometriosis. The LCS6 polymorphism is the first described
genetic marker of endometriosis risk.INTRODUCTION
Endometriosis is a benign, invasive, estrogen-dependent
disorder characterized by the presence of endometrial glands
and stroma outside the uterus. It is found in 5–15% of women of
reproductive age with more than 70 million affected worldwide
(Bulun, 2009; Gao et al, 2006; Hemmings et al, 2004).
Endometriosis has a dramatic effect on health and quality ofuctive Sciences, Yale
niversity School of
d Gynecology, Ponce
, USA
ental Biology, Yale
785-6309;
þ1 203-785-7819;life, causing chronic pelvic pain and infertility in up to 50% of
women with the disease (Fourquet et al, 2010). The yearly
medical costs and indirect economic impact total more than $22
billion in the United States alone (Practice Committee, 2006;
Simoens et al, 2007).
Although multiple medical therapies are available, there is no
established cure for endometriosis; all treatments suppress the
growth of both endometriosis and normal endometrium through
hormonal mechanisms; however, none target disease-specific
pathways. Surgical intervention has proven to be an effective
treatment; however, the estimated recurrence rate still remains
over 50% at 5 years after laparoscopic surgery (Hadfleld et al,
1996). In the United States, the mean delay in diagnosis is
approximately 11 years (Guo, 2009). There is an obvious need
to understand the biological basis of the disease in order to
devise specific treatments, allow early diagnosis and potentially
provide a means of prevention.
While the etiology and pathogenesis of endometriosis remain
an active area of investigation, there is a genetic predisposition
with a sevenfold risk of endometriosis in women whose mother
or sister has the disease (Moen & Magnus, 1993; Simpson &
Bischoff, 2002). It has been previously shown that some genesEMBO Mol Med 4, 206–217 www.embomolmed.org
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metriosis patients compared to normal endometrium (Kao et al,
2003; Taylor et al, 1999). However, no specific gene responsible
for the disease has been identified in humans (Moen & Magnus,
1993; Simpson & Bischoff, 2002). Two large genome-wide
association studies (GWAS) have linked disease susceptibility to
7p15.2 (a region between NFE2L3 and HOXA10) and to 9p21 in
the CDKN2BAS gene with odds ratios of 1.22 and 1.44,
respectively (Painter et al, 2011; Uno et al, 2010). Another
genome wide linkage study identified 10q26 as a locus
responsible for susceptibility to endometriosis (Treloar et al,
2005). Although these loci identify genetic linkage, they have
not identified genes demonstrated to be involved in the
pathophysiology of endometriosis.
No human studies have linked or identified alterations in the
gene responsible for the only known murine model of
spontaneous endometriosis. Activation of an oncogenic KRAS
gene in the murine ovarian surface epithelium results in the
de novo formation of lesions with endometriotic morphology
(Dinulescu et al, 2005). The authors of that study speculate that
RAS pathway activation by different mechanisms may play an
important role in endometriosis in humans. Moreover, a recent
study demonstrated that activation of mutated KRAS in
transplanted endometrium in mice triggered endometriosis
formation and long-term survival of the lesions (Cheng et al,
2011). However, despite thorough mutational analyses of KRAS
in human endometriosis by several groups, no activating
mutations in the coding regions of this gene have been found
(Amemiya et al, 2004; Otsuka et al, 2004; Vercellini et al, 1994;
Zhao et al, 2006).
We hypothesized that other possible mechanisms that alter
the regulation of KRAS gene expression may be involved in the
pathogenesis of human endometriosis. MicroRNAs (miRNAs)
are small non-coding RNAs that degrade or prevent translation
of their target genes by binding to the 30-untranslated regions
(UTRs) of mRNAs (Calin et al, 2004; Carletti & Christenson,
2009; Esquela-Kerscher & Slack, 2006). Single nucleotide
polymorphisms (SNPs) within miRNAs or miRNA binding sites
can alter mRNA stability or translation and, thereby, result in
various pathological processes including malignant transforma-
tion (Calin et al, 2004; Esquela-Kerscher & Slack, 2006; Yang
et al, 2008). KRAS is known to be regulated in a miRNA-
dependent manner (Johnson et al, 2005).
KRAS is a crucial target of let-7miRNAs including let-7a–g and
i (Johnson et al, 2005; Roush & Slack, 2008). KRAS is
downregulated through 10 let-7 complementary sites (LCS)
found in the 30-UTR of the KRAS gene (Chin et al, 2008). One of
these LCS (LCS6) is known to harbour a SNP (T!G in the fourth
position, rs61764370), which modifies let-7 binding in lung
cancer cells (Chin et al, 2008). The incidence of this SNP in the
general population is 5.8% (Chin et al, 2008). This variant allele
is associated with an increased risk of the development of non-
small cell lung cancer in people with only a moderate smoking
history and is also a marker of poor prognosis in oral cancer
(Chin et al, 2008; Christensen et al, 2009). Similarly, this SNP
has been identified in more than 25% of patients with ovarian
cancer and is a marker of an increased risk of developingwww.embomolmed.org EMBO Mol Med 4, 206–217epithelial ovarian cancer especially in BRCA-negative families
with hereditary breast and ovarian cancer syndrome (Ratner
et al, 2010).
Here, we hypothesized that the Ras pathway might be
activated by the presence of this previously identified SNP in
LCS6 in the 30-UTR of KRAS in patients with endometriosis. We
demonstrate the increased prevalence of this variant allele in
women with endometriosis. We show that the presence of this
SNP results in elevated KRAS protein expression causing
increased proliferation and invasion of human endometrial
stromal cells (hESC).RESULTS
Prevalence of the KRAS LCS6 variant in women
with endometriosis
To determine the prevalence of the KRAS variant allele in
women with endometriosis, we identified 150 subjects who
provided DNA samples. Subjects were an average age of 32.9
years and endometriosis was diagnosed an average of 7 years
prior to the study. Thirty-one percent had a family history of
endometriosis. DNA suitable for analysis was obtained from 132
subjects. The study included women with a current diagnosis or
history of endometrioma (n¼ 89) and/or peritoneal endome-
triosis (n¼ 43). Among those subjects with an endometrioma,
69% (n¼ 61) had co-existing peritoneal endometriosis. Staging
of disease was made according to the American Society for
Reproductive Medicine revised classification of endometriosis.
Surgical diagnosis of severe (stage IV) and moderate (stage III)
or minimal/mild (stage I/II) endometriosis was made in 56%
(n¼ 74), 33% (n¼ 43) and 11% (n¼ 15) of subjects, respec-
tively. 77% (n¼ 102) of patients had severe pain (pain which
interfered with everyday activities) and/or dysmenorrhea. 27%
(n¼ 36) of subjects were diagnosed with infertility. An irregular
menstrual cycle was present in 35% (n¼ 46) of subjects.
Chin et al determined the allele frequencies of the LCS6 SNP
using a collection of genomic DNA from 2433 healthy
individuals from a global set of 46 populations (Chin et al,
2008). An extensive database of genetic variations in these
samples can be found, along with the population descriptions, in
ALFRED (Cheung et al, 2000). They found that<3% of the 4,866
chromosomes, or 5.8% of people tested, had the G allele
(variant) at the LCS6 SNP site. The frequency of this allele varied
across geographic populations, with ‘European’ populations
exhibiting the variant allele most frequently (7.6% of the
chromosomes tested); African populations less frequently
(<2.0% of chromosomes tested) and ‘Asian’ and Native
American populations infrequently (<0.4% of chromosomes
tested; Chin et al, 2008).
Of the 132 women with endometriosis, 41 (31%) were found
to carry a variant allele at LCS6 in the KRAS 30-UTR that prevents
let-7 miRNA inhibition of KRAS. In subjects with ovarian
endometriomas, 23 of 89 had the variant LCS6 while 18 out of 43
women with peritoneal endometriosis carried this alternative
allele (25.8 and 41.8%, respectively). 5.3% of patients were
homozygous for the alternative allele (7 out of 132), which 2012 EMBO Molecular Medicine 207
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Table 1. Clinical characteristics of women with the non-variant and
variant KRAS alleles.
Variant KRAS
allele
Non-variant (wt)
KRAS allele
p-Value
Age 34.1 31.3 0.35
Stage IV disease 57% 56% 1
Years from diagnosis 9 6 0.31
Infertility 42% 18% 0.003
Irregular menses 28% 35% 0.34
Severe pain 42% 77% 0.001
Dysmenorrhea 42% 96% 0.0001
Dyspareunia 28% 69% 0.001
Subjects with the non-variant KRAS allele had severe pelvic pain, dyspareunia
and dysmenorrhea more frequently than patients with the alternative KRAS
allele. Subjects with the variant KRAS allele were more likely to be infertile.
Mean age and severity were not different. n¼41 subjects with KRAS variant
and 91 subjects with the WT allele.
208represents 17% of KRAS-variant-positive cases. There was no
difference in the mean age of subjects with KRAS non-variant
and variant alleles (Table 1). A total of 56 and 57% of subjects
with the non-variant and variant KRAS alleles, respectively,
were surgically diagnosed with severe (stage IV) endometriosis.
There was no difference in the frequency of endometriomas or
peritoneal endometriosis between the groups with the KRAS
variant or the non-variant allele. Subjects with the alternative
KRAS allele, however, more frequently had infertility (42%
vs.18% in the group with variant and non-variant KRAS allele,
respectively, p¼ 0.0033). In contrast, those with non-variant
KRAS allele complained of severe pain, dysmenorrhea and
dyspareunia more frequently than the group with the KRAS
variant allele. Those symptoms were found in 77%, 96% and
69% vs. 42%, 42% and 28% of women with the non-variant and 2012 EMBO Molecular Medicinevariant KRAS genes, respectively (p¼ 0.0001, p¼ 0.00001 and
p¼ 0.0001, respectively). Irregular menstrual cycles were
equally frequent in patients from each group. The subjects
were ethnically diverse and included 66 Caucasian, 9 black and
57 hispanic subjects. The rate of the KRAS variant was not
significantly different between ethnic groups.
In summary, the KRAS variant that prevents let-7 miRNA
inhibition of KRAS was significantly increased in women with
endometriosis. The prevalence of the KRAS variant allele in our
endometriosis patient cohort is significantly higher than
expected in any existing geographic population, supporting
the hypothesis that this variant allele is a marker of increased
endometriosis risk.
Effect of the LCS6 variant allele on KRAS and let-7 expression
Quantitative polymerase chain reaction (after reverse transcrip-
tion) (RT-PCR) was used to determine the level of KRASmRNA in
cultured hESC from women without endometriosis, women with
endometriosis heterozygous for the variant allele, and women
homozygous for the wild-type (WT) allele (n¼ 10 subjects per
group). hESC from women without endometriosis were found to
express approximately threefold lower levels of KRAS mRNA
compared to both hESC from women with endometriosis carrying
WT KRAS (KRAS/Actin: 0.001 0.0002 vs. 0.003 0.0004;
p¼ 0.0007) and 10-fold lower mRNA levels compared to those
carrying the variant KRAS allele (0.01 0.002; p¼ 0.0001). KRAS
mRNA was approximately threefold higher in hESC of subjects
with the variantKRAS LCS6 compared to hESC from subjects with
the non-variant allele (p¼ 0.0049; Fig 1a). Western blot analysis
showed that hESC from women with the KRAS SNP had a 2.8-fold
increase in KRAS protein compared to endometrium carrying the
non-variant allele (Fig 1b).let-7 is known to bind to the non-
variant and not the variant LCS6 allele preventing KRAS protein
synthesis. To assess the possibility of compensatory changes inFigure 1. KRAS expression in hESCs obtained from
endometrium of 10 women without
endometriosis, eutopic endometrium of 10
women with endometriosis carrying WT KRAS and
10 women with endometriosis carrying the
variant allele of KRAS gene at the LCS6 site.
A. q-RT-PCR results show comparatively low levels
of KRAS mRNA in normal endometrium, increased
KRAS mRNA in hESC from women with endo-
metriosis and the WT KRAS allele (p¼0.0007)
and highest expression of KRAS mRNA in hESC
carrying the variant KRAS allele (p¼ 0.00018
when compared to normal hESC, p¼0.0049
when compared to hESC from endometriosis
patients with WT allele). (, difference is signifi-
cant when compared to normal hESC; , differ-
ence is significant when compared to hESC from
women with endometriosis homozygous for the
WT KRAS allele).
B. Western blot results show a 2.8-fold increase in
KRAS protein in hESC with the variant allele.
EMBO Mol Med 4, 206–217 www.embomolmed.org
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Figure 2. let-7 miRNA family expression in hESC from 10 subjects without endometriosis (normal controls), 10 subjects with endometriosis carrying WT
KRAS and 10 subjects with endometriosis and the variant allele of KRAS gene. q-RT-PCR results show a trend towards decreased transcript levels of all let-7
miRNAs in hESC from subjects with endometriosis compared to normal hESC from subjects without endometriosis (normal control). Endometrial cells from
subjects with endometriosis with the LCS6 variant in the KRAS gene showed lower levels of let-7a, b and e compared to hESC from endometriosis with non-variant
KRAS (p¼ 0.0047, 0.003 and 0.05, respectively). let-7a and b were also lower in KRAS-variant cells from women with endometriosis compared to normal hESC
(zp¼0.05 and 0.02, respectively).let-7miRNAs in the setting of the variant allele and elevated KRAS
protein, we determined the level of let-7a–g miRNAs (Fig 2).
Cultured endometrial stromal cells from women with endome-
triosis with the LCS6 variant in the KRAS gene showed lower
levels of let-7a, b and e (0.26 0.009, 0.07 0.01 and 0.08 0.02,
respectively), compared to hESC from women with endome-
triosis with non-variant KRAS (0.21 0.05, 0.29 0.02,
0.21 0.029, respectively; p¼ 0.0047, 0.003 and 0.05, respec-
tively). let-7a and b were also lower in KRAS variant cells from
endometriotic women compared to normal hESC (0.29 0.188,
0.53 0.23, respectively; p¼ 0.05 and 0.02, respectively).
Compared to hESC isolated from normal endometrium, hESC
from women with endometriosis exhibited lower levels of let-7
family miRNA. These alterations in let-7 in the presence of the
KRAS variant allele could be a result of a feedback mechanism or
due to another unidentified independent factor, but do agree with
prior published findings of lower let-7 in KRAS variant-associated
lesions.
Effect of the LCS6 variant on the expression of KRAS using a
luciferase reporter assay
To demonstrate that the increased level of KRAS protein seen in
cultured hESC from subjects with the KRAS variant was in factwww.embomolmed.org EMBO Mol Med 4, 206–217due to altered let-7 binding to the mutant LCS6, we introduced
an siRNA construct designed to rescue let-7 activity by binding
to the altered LCS6. Normal hESCs were co-transfected with a
luciferase reporter construct carrying the variant LCS6, the
siRNA or a siRNA negative control (Fig 3). Luciferase activity in
the cells transfected with a reporter carrying the KRAS variant
allele was approximately 30-fold greater than the activity from
the reporter with the WT allele (relative luciferase activity:
0.1 0.001 vs. 2.9 0.05). The siRNA targeting the LCS6 variant
RNA reduced the luciferase activity in the cells with the reporter
containing the KRAS LCS6 variant by 70% (to 0.9 0.13;
p¼ 0.045).
Cell proliferation and invasion
We assessed proliferation in the presence of the KRAS LCS6
variant allele using BrdU labelling. This assay showed a 71%
increase of BrdU labelling in KRAS LCS6 variant hESC, indicative
of an increased proliferation rate of endometrial cells from
women with the variant allele compared to those with the non-
variant allele (absorbance 0.48 0.08 vs. 0.28 0.02; p¼ 0.04;
Fig 4a).
To determine the invasion capacity of these cells, we assessed
the percentage of cells that invaded through ECM gel. The 2012 EMBO Molecular Medicine 209
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Figure 3. The effect of siRNA mimicking let-7 action on luciferase
expression from the reporter plasmid carrying WTor variant KRAS allele in
Dual Luciferase Reporter assay. Normal hESC were co-transfected with pGL3
vector carrying the variant LCS6 of the KRAS gene and either siRNA modified to
bind the variant LCS6 or a negative control RNA sequence. Luciferase activity
from the reporter plasmid carrying the KRAS-variant allele was greatly
increased compared to that from a reporter plasmid containing non-variant
allele at baseline. There was a 70% reduction in luciferase activity when the
KRAS-variant allele was co-transfected with siRNA designed to bind the LCS6
site (p¼ 0.045). No significant decrease in luciferase activity was obtained
after co-transfecting this reporter plasmid with a control RNA sequence. The
pGL3 control vector was used to assess transfection efficiency. Transfection
with pGL3 carrying non-variant LCS6 of KRAS gene resulted in minimal
luciferase activity likely due to inhibitory effects of endogenous let-7 miRNAs.
Each experiment was carried out in duplicate in three separate experiments
using cells from individual subjects. WT KRAS, hESC transfected with WT KRAS;
KRAS V, hESC transfected with KRAS variant allele; KRAS Vþ siRNA, hESC co-
transfected with KRAS variant allele and siRNA; KRAS Vþ siRNA NC, hESC co-
transfected with KRAS variant allele and siRNA negative control; pGL3 PC, hESC
transfected with pGL3 control vector.
210normalized absorbance (mean absorbance in sample wells
minus mean absorbance in negative control wells) was
0.089 0.006 for hESC from control subjects, 0.118 0.019
for hESC from subjects with endometriosis carrying WT KRAS
allele and 0.175 0.026 for hESC from subjects with endome-
triosis carrying variant KRAS allele. Normalized absorbance in
positive control wells (100% invasion) was 1.16 0.028. The
percent of invading cells was further calculated as 7 0.5,
10 1.8 and 15 2.4% in samples from women without
endometriosis, women with endometriosis and non-variant
KRAS LCS6 and women with endometriosis and the variant
KRAS LCS6 (Fig 4b). Invasion capacity of normal hESC and hESC
from women with endometriosis without the variant were not
significantly different, however, the cultured endometrial cells
with the KRAS LCS6 variant allele invaded at a significantly
increased rate compared to normal hESC (15% vs. 7%,
respectively, p¼ 0.013). 2012 EMBO Molecular MedicineThe KRAS LCS6 variant allele in a murine endometriosis model
To evaluate differences in growth parameters in vivo, capacity
for endometriotic lesion formation as well as histopathological
and molecular characteristics of cultured endometrial stromal
cells containing non-variant and variant alleles of the KRAS
gene, a mouse model of endometriosis was used. We
transplanted hESC obtained from subjects with and without
the LCS6 variant under the kidney capsule of immune-deficient
mice. Both non-variant and LCS6 variant cells formed
endometriosis-like lesions with both glandular and stromal
components (Fig 5a). The glandular component likely origi-
nated from progenitor stem cells in the culture as recently
described (Cervello et al, 2011). Glandular cells are not
identified in these cultures by the third passage, however, we
cannot exclude a small number of contaminants (Taylor et al,
1998). Analysis of proliferation marker PCNA showed more
cells (both epithelial and stromal) with stained nuclei in
the lesion derived from LCS6 variant cells compared to those
derived from non-variant cells. The percentage of stained nuclei
in epithelium of lesions carrying variant KRAS allele was
54 5% vs. 8 1% in lesions created by non-variant hESC
(p¼ 0.02). Stromal cells from lesions with the SNP exhibited
56 5% of nuclei staining while in the lesions with WT KRAS,
the percentage of positively stained nuclei was 34 6%
(p¼ 0.043; Fig 5b). These results suggest increased proliferation
of cells harbouring the variant allele and were consistent with
the results of the in vitro proliferation experiment. Apoptosis
was assessed using cleaved caspase 3, and the amount of
cleaved caspase 3 was equivalent in lesions derived from cells
with either non-variant or LCS6 variant alleles (data not shown).
Proliferation was increased without an increase in apoptosis in
the LCS6 variant lesions.
Progestins are commonly used to treat endometriosis and
progesterone resistance has been described in this disease
(Bulun et al, 2006; Cakmak & Taylor, 2010). To determine if
alterations in the expression of sex steroid receptors were seen
in the presence of the variant allele, we assessed estrogen
receptor alpha (ERa) and progesterone receptor (PR) A and B.
ERa levels were similar between lesions derived from cells with
or without the variant LCS6 allele (data not shown). The number
of nuclei positively stained for PR was decreased in the lesions
with KRAS variant allele compared to the lesions created by WT
hESC in both epithelium (35 4% vs. 75 3%, respectively,
p¼ 0.02) and stroma (13 8% vs. 78 6%, respectively,
p¼ 0.028; Fig 5c). The KRAS LCS6 variant cells retain the
receptor for estrogen, which drives proliferation in endometrial
cells; however, these cells show decreased PR, which drives
differentiation.DISCUSSION
In this study, we have identified a novel gene mutation
associated with endometriosis. A variant SNP in the LCS6 let-7
miRNA binding site of the KRAS 30-UTR was found in 31% of all
cases of endometriosis, which is significantly higher than the
5.8% incidence observed in world populations. This variantEMBO Mol Med 4, 206–217 www.embomolmed.org
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Figure 4. The effect of the KRAS variant allele on proliferation and invasion capacity of hESC.
A. The effect of the KRAS variant allele on proliferation of hESC from women with endometriosis as determined by BrdU incorporation. There was a 71% increase
(p¼0.04) in the BrdU label in hESC with the variant allele (n¼ 5) versus WT KRAS LCS6 (n¼ 5). These results indicated an increase in cell proliferation rate of
hESC containing the mutant KRAS LCS6.
B. The effect of the KRAS variant allele on hESC invasion capacity. An invasion assay in which hESC from women with and without endometriosis and with the WT
non-variant or the alternative KRAS allele was used to determine the ability to invade extracellular matrix. There was a significant increase in the invasion of
hESC containing the variant allele (n¼9) compared to hESC without the variant allele (n¼ 6) (p¼ 0.013). The difference between normal cells (n¼6) and cells
from endometriosis with WT KRAS was not significant.allele is, therefore, potentially contributing to nearly one third of
all endometriosis cases. Subjects with the non-variant KRAS
allele more commonly presented with pain and dysmenorrhea
than those with the variant allele; this may be due to the higher
incidence of peritoneal endometriosis (as a proportion of total
endometriosis), which is more likely to be symptomatic than are
ovarian endometriomas. Subjects with the KRAS variant more
often presented with infertility. Stage IV endometriosis,
however, was equally common among subjects in each group.
This finding provides a mechanism for the pathogenesis of
endometriosis in women with this functional mutation. Loss of
the normal LCS6 let-7 binding site was associated with increased
transcription and translation of KRAS. Ras proteins are crucial
regulators of tyrosine kinase mitogenic and oncogenic activity.
Effects of Ras activation include increased cell survival and
proliferation (Khosravi-Far & Der, 1994; Schubbert et al, 2007).
In this study, we demonstrate that the presence of the variant
allele leads to a higher proliferation and invasion rate in
endometrial cells. These properties may facilitate the invasion of
endometrial cells into peritoneum and ovarian cortex. Thiswww.embomolmed.org EMBO Mol Med 4, 206–217mechanism supports the most accepted theory for the origin of
endometriosis – retrograde menstruation and subsequent
implantation and invasion of susceptible tissues (Giudice &
Kao, 2004). The fact that only a portion of women develop this
disease despite the nearly universal occurrence of retrograde
menstruation could be explained by the presence of this allele.
Moreover, in the in vivo model of endometriosis, endometrial
stromal cells harbouring the variant allele demonstrated a more
aggressive behaviour. Cells containing the variant allele
produced lesions that proliferated more and expressed lower
levels of PR, which in turn may contribute to the diminished
responsiveness to progesterone treatment. The behaviour of the
variant cells in this model resembled those in mice with an
activated KRAS gene that form endometriosis de novo (Dinu-
lescu et al, 2005). Limitations of our model include the
variability in hormone levels through the estrous cycle despite
timing by vaginal cytology; however, this model also closely
resembles the normal hormonal exposure seen in women. The
activation of KRAS signalling through the LCS6 mutation
explains the inability to find activating mutations in the coding 2012 EMBO Molecular Medicine 211
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Figure 5. Morphological and molecular features
of endometriotic lesions containing the WT non-
variant or variant alleles of the KRAS LCS6.
Cultured endometrial stromal cells were injected
under the kidney capsule of immunodeficient mice.
A. Morphological appearance of the lesions under
the kidney capsule of immune deficient mice
1 month after transplantation of hESC either with
or without the variant KRAS. In all cases the
transplanted endometrial cells formed endome-
triosis lesions with both glandular and stromal
components.
B. Proliferation marker expression in endometriotic
lesions in mice. Nuclear staining for PCNA was
more prominent in epithelium and stroma of the
lesions formed by KRAS variant positive cells
(54 5% and 566% in epithelium and stroma,
respectively), compared to those derived from
normal cells (84% and 34 6% in epithelium
and stroma, respectively; p¼0.02 and p¼ 0.043)
indicating higher proliferation levels in these
cells.
C. PR expression in endometriotic lesions with WT
non-variant or variant KRAS allele in mice.
Lesions created by hESC carrying KRAS variant
allele were characterized by a smaller number of
nuclei stained positively for PR in both glandular
and stromal cells. The epithelium of the lesions
with variant cells was found to have only
355% of nuclei positively stained compared to
753%, in the lesions with WT KRAS (p¼0.02).
Only 138% of nuclei of stromal cells in KRAS
variant lesions were found to express PR com-
pared to 787% in the non-variant lesions
(p¼ 0.028). Scale bar represents 25mm.
212regions of KRAS in humans with endometriosis. The mouse
model of endometriosis can now be reconciled with the human
disease, both caused by activating mutations disrupting
regulation of the KRAS gene.
This variant in the let-7 binding site of KRAS has been
established as a marker for predisposition to ovarian cancer
(Ratner et al, 2010). This lends support to the theory that certain
types of ovarian cancer may arise from endometriosis and helps
to explain the increased risk of ovarian cancer in women with
endometriosis (Nezhat et al, 2008). This variant SNP may be an
early marker of those endometriosis patients with an increased
risk of ovarian cancer, a hypothesis that will require additional
validation.
Two large GWAS did not identify this SNP in women with
endometriosis. The LCS6 polymorphism is not on the Illumina
chip used in the larger European/US study. In addition, these
studies confirmed the diagnosis of endometriosis by review of
the medical records in a small minority of the subjects; and in
the control group endometriosis status was not determined and
can be expected to be approximately 10% in reproductive aged
women. In contrast, all endometriosis subjects in this study
were identified prospectively at the time of surgery and were
thus clinically well annotated. Although GWAS studies are
important for discovery of regions of the genome important in
disease, they have not always proven to be useful in validation 2012 EMBO Molecular Medicineof functional markers due to the all-inclusive approach applied
for cases and controls.
The KRAS pathway presents a potential therapeutic target for
treatment of endometriosis. Our results demonstrate that
synthetic small RNAs complementary to the variant allele will
bind the LCS6 site and reduce reporter gene expression,
suggesting a possible therapy for endometriosis. siRNA has
been used as a drug because of its ability to induce specific, yet
transient and reversible effects (Shim & Kwon, 2010).
In conclusion, a SNP in the let-7miRNA binding site in 30-UTR
of the KRAS gene is a marker of endometriosis risk, explains the
pathogenesis of endometriosis in the subgroup of patients with
the SNP, provides a novel method of early endometriosis
diagnostics, ovarian cancer prevention and offers potential
treatment opportunities.MATERIALS AND METHODS
Subjects and sample collection
From 2008 to 2010, a total of 150 DNA samples were collected from
subjects diagnosed with endometriosis (ovarian or peritoneal) 132 of
which were tested for the presence of K-Ras variant allele. DNA samples
were received from subjects recruited at either Ponce School of
Medicine and Health Sciences (PSMHS), Ponce, Puerto Rico (n¼48) orEMBO Mol Med 4, 206–217 www.embomolmed.org
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Table 2. Primers used for quantitative RT-PCR
Primers Sequence
KRAS forward tgaggactggggagggcttt
KRAS reverse aggcatcatcaacaccctgtct
ACTB forward gaagatcaagatcattgctc
ACTB reverse aacgcaactaagtcatagtc
U6 forward ctcgcttcggcagcaca
U6 reverse aacgcttcacgaatttgcgt
let-7a tgaggtagtaggttgtatagtt
let-7b tgaggtagtaggttgtgtggtt
let-7c tgaggtagtaggttgtatggtt
let-7d agaggtagtaggttgcatagtt
let-7e tgaggtaggaggttgtatagtt
let-7f tgaggtagtagattgtatagtt
let-7g tgaggtagtttgtacagttthe Yale University School of Medicine (n¼102). The study included
women with a current diagnosis or history of endometrioma (n¼89)
and/or peritoneal endometriosis (n¼43). In all cases the diagnosis was
made by biopsy; the lesion was surgically excised and the diagnosis of
endometriosis was confirmed histologically. DNA was extracted from
saliva, blood or tissue. Written informed consent was obtained from all
participants. Approval for the experiments was obtained from the Yale
University and the PSMHS Institutional Review Boards as well as from
Yale University IACUC for mouse surgery protocol.
Evaluation of the LCS6 SNP in the 3(-UTR of the KRAS gene
DNA was isolated using the DNeasy Blood and Tissue kit or QIAamp
DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. For high-throughput genotyping, the isolated
DNA samples were amplified using TaqMan PCR assays designed
specifically to identify the T or G allele of the LCS6 SNP of KRAS gene
(Applied Biosystems, Foster City, CA) as was described previously (Chin
et al, 2008). Each assay was conducted in duplicate. Positive Results
were confirmed by sequencing of the LCS6 region.
Tissue collection and cell culture
Endometrial biopsies were obtained from women with surgical and
histological diagnosis of endometriosis. Biopsies were performed using
the Pipelle catheter (CooperSurgical, Trumbull, CT) both from women
positive for KRAS variant allele and women with WT KRAS gene.
Endometrium from women without surgical evidence of endome-
triosis but with possible other benign gynecological conditions (e.g.
fibroids, benign ovarian cysts) who tested negative for the presence of
variant allele were used as controls. Briefly, endometrium was finely
minced and cells were dispersed by incubation in HBSS containing
HEPES (25mm), 1% penicillin/streptomycin, collagenase (1mg/ml,
15U/mg) and DNase (0.1mg/ml, 1500U/mg) for 60min at 378C with
agitation and pipetting. Endometrial cells were pelleted, washed and
suspended in Ham’s F12:DMEM (1:1) containing 10% FBS, 1%
penicillin/streptomycin and 1% Amphotericin B. A mixture of
endometrial cells (epithelial and stromal) were passed through a
40-mm sieve which allowed stromal cells to pass through while
epithelial cells are retained on the sieve (Millipore, Billerica, MA). hESC
were plated into 75 cm2 Falcon Tissue Culture flasks (BD Biosciences,
Franklin Lakes, NJ). Cultured hESC at 3–5 passages were used for q-RT-
PCR, proliferation, invasion, reporter assays and in the murine model.
In each assay the number of passages was identical between the
variant and control group.
As it has been previously shown by other investigators that stomal
component of endometrium plays a crucial role in regulating
endometrial homeostasis and controlling epithelial growth, hESC were
chosen for use in all cell culture experiments (Arnold et al, 2001).
Moreover it is well established that it is the defect in stromal cells which
is responsible for defective estradiol metabolism in eutopic and ectopic
endometrial tissue in patients with endometriosis (Cheng et al, 2007).
For all experiments hESC heterozygous for the variant allele were used
and compare to either normal hESC or hESC from women with
endometriosis and who were homozygous for WT KRAS allele.
Quantitative RT-PCR
To assess KRAS mRNA levels total RNA was extracted from primary
cultured endometrial stromal cells using the Qiagen RNeasy isolationwww.embomolmed.org EMBO Mol Med 4, 206–217kit (Qiagen). The experiment included hECS from six normal subjects,
six subjects with endometriosis carrying WT KRAS allele and six
subjects carrying the variant KRAS allele. All samples were treated with
RNase-free DNase (Ambion, Austin, TX) to remove the possibility of
genomic DNA contamination. RNA samples were analysed by
spectrophotometry to determine RNA concentration. mRNA (0.5mg)
was reverse-transcribed into cDNA using the iScript cDNA Synthesis
Kit at 468C for 40min in a reaction mixture of 20ml (Bio-Rad
Laboratories, Hercules, CA). The resultant cDNA mixtures were stored
at 208C. Gene transcripts were amplified by real-time PCR using the
Bio-Rad iCycler iQ system (Bio-Rad Laboratories). All primers were
obtained from W. M. Keck Oligonucleotide Synthesis Facility, Yale
University (Table 2). Real-time PCR was performed using the iQ SYBR
Green Supermix Kit (Bio-Rad Laboratories). Reaction mixture included
cDNA template (1mg), forward and reverse primers, RNase-free water
and the iQSYBRGreen Supermix, for a final reaction volume of 25ml.
The thermal cycling conditions were initiated by uracil-N-glycosylase
activation at 508C for 2min and initial denaturation at 958C for
10min, then 40 cycles at 958C for 15 s and annealing at 56.58C for
30 s. Melting analysis was performed by heating the reaction mixture
from 74 to 998C at a rate of 0.2 C/s. Threshold cycle (Ct) and melting
curves were acquired by using the quantitation and melting curve
program of the Bio-Rad iCycler iQ system (Bio-Rad Laboratories). Only
data with clear and single melting peaks were taken for further data
analysis. Each reaction was performed in triplicate. The mRNA level of
each sample was normalized to b-actin (ACTB) mRNA. Relative mRNA
level was presented using the formula 2DCt.
For miRNA detection total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA). We employed the Poly (A) RT-PCR method using
Invitrogen NCode miRNA First-Strand cDNA Synthesis MIRC-50 kit
(Invitrogen). Conventional RT-PCR was used to assay miRNA levels
with the specific forward primers to let-7a–g and the universal reverse
primer complementary to the anchor primer. Anchor RT primer was
used as the template for negative control and U6 small nuclear RNA
was used as a control to determine relative miRNA expression. The
real-time PCR profile was as described above, except for a melting
temperature of 598C.
Western blot analysis
Cultured endometrial stromal cells from five women with endome-
triosis carrying WT KRAS and five women with endometriosis with 2012 EMBO Molecular Medicine 213
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214variant KRAS were lysed in Cell Lysis Buffer (Cell Signaling
Technologies, Boston, MA) and centrifuged at 12,000 rpm for 2min
at 48C, and the supernatant was collected. The protein content was
quantified by the BCA assay method by using a protein assay kit (Bio-
Rad Laboratories, Richmond, VA.). Aliquots (20mg) were loaded onto
4–20% gradient polyacrylamide gel in MOPS buffer system (Invitro-
gen) and transferred to a nitrocellulose membrane by using a
Transblot apparatus (Bio-Rad Laboratories) at 35 V overnight at 48C.
Subsequently, the membranes were incubated in blocking buffer (5%
milk) for 1 h and then immunoblotted with mouse monoclonal KRAS
antibody (1:200, ab55391, Abcam, Cambridge, MA) and Pan Actin
antibody (1:25,000, 4968, Cell Signaling Technologies) overnight. After
incubation with the primary antibody, the membranes were washed
three times for 15min with TBS [10mM Tris–HCl (pH 7.4), 0.5M NaCl]
plus Tween 20 (0.2% v/v; TBST) and were incubated for 2 h in the
corresponding HRP conjugated secondary antibody (1:2000; Invitro-
gen). The membranes were washed three times for 5min in TBST.
Proteins were detected with enhanced chemiluminescence (PerkinEl-
mer, Waltham, MA). Quantification was performed using the ImageJ
program.
Transfection and luciferase assay
pGL3 derivatives containing nearly the entire KRAS 30-UTR (KRAS WT)
and KRAS variant LCS6 were created as follows. KRAS WT includes
3910 bp of the KRAS 30-UTR, which was amplified from human
genomic DNA using the forward primer SMJ104 (ctagctagcatacaatttg-
tacttttttcttaaggcatac) and reverse primer LCJ5 (ctagctagctcaatgca-
gaattcatgctatccag). NheI restriction sites were included on the 50-ends
of the primers for convenient cloning. The product was first cloned
into the TOPO cloning vector (Invitrogen) and then subcloned into
pGL3 (Ambion) for use in subsequent luciferase assays. The luciferase
reporter with the variant LCS6 KRAS 30-UTR (KRAS mLCS6) was
constructed through site-directed mutagenesis of KRAS WT using
GeneTailor (Invitrogen). Normal endometrial stromal cells were plated
in 12-well plates at 60% confluency. The adherent cells were co-
transfected with 1mg of luciferase reporter with variant K-Ras allele
and a small interfering RNA (0.4 nM) designed to bind to the variant
LCS6 K-Ras allele (ggacuggaguucacuacgugu). Qiagen AllStars Negative
Control siRNA (0.4 nM) was used as negative control. To exclude the
possibility that the endogenous levels of let-7 family miRNAs were not
sufficient to down regulate KRAS a control set of cells was transfected
with pGL3 basic derivative carrying WT regulatory region of K-Ras
gene. pGL3 control vector was used as positive control of transfection
efficiency. All cells were co-transfected with renilla vector (50 ng)
using Fugene Transfection Reagent (Roche, Basel, Switzerland) using a
DNA/Fugene transfection reagent volume ratio of 1:3. Luciferase
activity was measured after 24 h of incubation according to the
manufacturer’s protocol using the Dual-Glow Luciferase assay system
(Promega, Madison, WI). Firefly luciferase activity was normalized to
renilla luciferase activity values for each sample. Experiments were
performed three times in triplicate. The Mann–Whitney U-test was
used for statistical analysis of the data.
Proliferation assay
Proliferation assay was performed with 5-bromo-20-deoxy-uridine
Labeling and Detection Kit III (Roche Applied Science, Germany).
0.5105 of hESC with or without variant allele were plated into a 2012 EMBO Molecular Medicine96-well plates. After culturing hESC for 48 h 10ml of BrdU labelling
solution was added into each well and incubated for 4 h. Then the
culture medium containing the labelling solution was removed, cells
were washed with serum containing wash medium and fixed with
200ml of precooled 0.5M ethanol in HCl for 30min at 208C. The
cells were washed three times with serum containing medium and
incubated with 100ml of nucleases working solution per well for
30min at room temperature in a water bath. Following three
washes, 100ml of of anti-BrdU-POD, Fab fragments and working
solution were added. After 30min of incubation at room tempera-
ture the antibody conjugate was removed and the cells were washed
three times with washing buffer and incubated with 100ml of
peroxidase substrate per well. When positive samples showed
distinctive green colour compared to negative control wells
colorimetric analysis was performed using a microplate reader at
405 nm with a reference wavelength of approximately 490 nm (Bio-
Rad Laboratories). The assay was performed three times in
triplicate using hESC obtained from six different subjects in each
group. The Mann–Whitney U-test was used for statistical analysis of
the data.
Invasion assays
The invasion capacity from serum free towards serum containing
medium through extracellular matrix gel and 8mm pore membrane
was analysed using the Millipore Colorimetric Migration Assay on 24-
well plates (BD Falcon, Franklin Lakes, NJ, USA). Briefly, the membrane
of each insert was covered with 100ml of ECM gel (Sigma–Aldrich, St.
Louis, MO) and the cells were kept in serum free medium (DMEM
F12þ1% penicillin/streptomycinþ1% Amphotericin B) for 24 h.
2105 hESC from women without endometriosis and with
endometriosis with WT or variant KRAS alleles were seeded into the
inserts and incubated for 48 h. The lower chamber for this assay
consisted of 24-well tissue culture plates (BD Falcon), which contained
500ml of DMEM/F12 (1:1) with 10% FBS, 1% Pen/Strep and 1%
Amphothericin B. For the control hESC (2105) were plated directly
into the lower chamber which represented 100% invasion. Invaded
cells were stained, collected and lysed according to the manufacturer’s
instructions. Optical densities were read in triplicate at 560nm using
a Bio-Rad Laboratories (Hercules, CA, USA) plate reader. To determine
the relative percent of invasion, results were compared to the 100%
invasion control. Each experiment was performed three times in
triplicate using specimens from six subjects without endometriosis, six
subjects with endometriosis carrying WT KRAS allele and nine subjects
with endometriosis carrying variant KRAS allele. The Mann–Whitney
U-test was used to assess the significance of the difference in the
acquired data.
Murine endometriosis model
Female 6–8-week-old immune-deficient mice (CB17SCID) were
purchased from Charles River Laboratory. Experimental endometriosis
was created in six mice. All surgeries and tissue collection were
synchronized by use of vaginal cytology. All mice were operated on in
their proestrous phase. In three mice endometriosis was created using
cultured endometrial stromal cells from three different subjects with
endometriosis and who tested positive for the KRAS variant SNP. In the
other three mice endometriosis was created using cultured endome-
trial stromal cells from three different subjects with endometriosis butEMBO Mol Med 4, 206–217 www.embomolmed.org
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The paper explained
PROBLEM:
Endometriosis is a common, benign gynecological disorder,
which is a frequent cause of chronic pelvic pain and infertility in
5–15% of reproductive age women. Although studied for many
years, the exact pathogenesis as well as etiology of this disease
remain unclear. It has been previously shown that activation of
the KRAS gene caused de novo formation of endometriosis in
mice, however, no activating mutations were found in the coding
region of this gene in human endometriosis.
RESULTS:
The authors hypothesized that there might be an activating
mutation in the regulatory regions of KRAS gene causing
excessive production of the protein with subsequent activation
of the Ras pathway. 132 women with endometriosis were
evaluated for a newly identified polymorphism in a miRNA let-7
binding site in the 30-UTR of the KRAS gene, which has been
previously associated with an increased risk of lung and ovarian
cancer. Thirty-one percent of the subjects were found to carry
this variant allele compared to only 5.8% of the general
population. The presence of this mutation was found to be
associated with higher KRAS mRNA and protein levels and lower
let-7 levels in endometrial stromal cells of women with
endometriosis as well as an increased proliferation rate and
invasion capacity of these cells.
IMPACT:
This study identified a novel gene mutation, which is associated with
up to one third of endometriosis cases. This mutation potentially
represents a new therapeutic target for endometriosis as well as the
basis of a potential screening method for endometriosis risk.negative for the SNP (i.e. possessing the normal KRAS LCS6). Cells were
cultured as described above, passaged 3–5 times, used at 100%
confluency and harvested using 0.05% trypsin/EDTA. Cells were
counted manually with a hemocytometer. The protocol for mouse
kidney capsule cell transplantation was adopted and modified from
Szot et al (Szot et al, 2007). Briefly, 1106 cells were suspended in
20ml normal saline and transferred to PE50 tubing system (BD
Biosciences). The tubing was placed into 15ml Falcon tubes and
centrifuged at 1000 rpm to form a pellet. The tubing was maintained
at 378C until the procedure was performed. Each mouse was
anaesthetised with intraperitoneal injection of xylazine/ketamine
solution (100 and 10mg/kg, respectively). Meloxicam was used for
analgesia (0.2mg/kg). The kidney was exteriorized and normal saline
solution was injected in the peritoneal cavity to avoid dehydration.
The kidney capsule was incised using a 27 gauge needle, the tubing
containing the cell pellet inserted into the incision and the pellet was
released under the kidney capsule. Thermocautery was used to close
the kidney incision. The kidney was put back into the abdominal cavity
and the abdominal wall was sutured. The skin was closed using a
surgical stapler. After 4 weeks mice were sacrificed and the kidneys
harvested, formalin fixed and paraffin embedded. Five micron sections
were stained using haematoxylin and eosin (H&E) or used for
immunohistochemistry (IHC) as described below. The experiment
protocol was approved by Yale Institutional Animal Care and Use
Committee.
Immunohistochemistry
IHC was conducted on formalin-fixed paraffin-embedded mouse
kidneys containing transplanted hESCs that had either the variant or
normal LCS6 allele of the KRAS gene. Sections were deparaffinized, and
dehydrated through a series of xylene and ethanol washes. Each
specimen was stained with H&E for histological evaluation. For IHC
analysis, after a 5-min rinse in distilled water, an antigen-presentingwww.embomolmed.org EMBO Mol Med 4, 206–217step was performed by steaming the slides in 0.01mole/l sodium
citrate buffer for 20min, followed by cooling for 20min. Slides were
rinsed for 5min in PBS with 0.1% Tween 20 (PBST), and sections were
circumscribed with a hydrophobic pen. Endogenous peroxidase was
inactivated by incubation in 3% hydrogen peroxide for 5min, followed
by a 5-min PBST wash. After a preincubation with 2% normal goat or
horse serum to block non-specific sites, sections were incubated with
primary antibodies in a humidified chamber for 18 h at 48C.
Antibodies used were against PCNA, ERa, PR (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and Cleaved Caspase-3 (Asp175; Cell Signaling
Technology, Beverly, MA). Slides were then incubated with the
appropriate biotin conjugated secondary antibodies followed by
avitin–biotin–horseradish peroxidase complex and diaminobenzidine
tetrahydrochloride before counterstaining with Gill’s haematoxylin
(ABC kit; Vector Laboratories, Burlingame, CA). Negative control
sections were processed in an identical manner but substituting
primary antibodies with normal rabbit IgG. All negative control
sections showed no colour reaction. The number of stained nuclei was
counted separately in epithelium and stroma in five high-power fields
on each slide by three-independent researchers and averaged for each
experimental animal. The Mann–Whitney U-test was used to
determine the significance of differences between experimental
groups.
Statistical analysis
Chi-squared test was used to compare the frequencies of clinical
symptoms among the groups of patients with non-variant and
alternative KRAS allele. T-test was used to evaluate statistical
significance of experiments used to asses KRAS mRNA and let-7
miRNA. The Mann–Whitney U-test was used to assess the significance
of the differences in proliferation, invasion and luciferase activity and
to compare IHC staining indices. Reported are mean standard error
of the mean (SEM). 2012 EMBO Molecular Medicine 215
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